

Figure 1: Treatment details for all patients

A: Treatment schema for patients presenting after primary nephrectomy.

Stage 1 Intermediate Risk:	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 10
Stage 2 low /Intermediate Risk:	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 11; then 3 weekly x 5; Actinomycin-D (45mcg/kg) 3 weekly x 9 (starting week 2)
Stage 3 Intermediate Risk:	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 11; then 3 weekly x 5 Actinomycin-D (45mcg/kg) 6 weekly x 5 (starting week 2) Doxorubicin (50mg/m <sup>2</sup> ) 6 weekly x 4 (starting week 7)
Stage 3 High Risk:	Carboplatin (600mg/m <sup>2</sup> )/Etoposide (300mg/m <sup>2</sup> ) 6 weekly x 6 on weeks 4, 10, 16, 22, 28 and 34 Cyclophosphamide (500 mg/m <sup>2</sup> )/Doxorubicin (50mg/m <sup>2</sup> ) 6 weekly x 6 on weeks 1, 7, 13, 19, 25 and 31
Stage 4 (All):	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 6 Actinomycin-D (45mcg/kg) week 1,3 & 5 Doxorubicin (50mg/m <sup>2</sup> ) week 1 & 5 Evaluation of metastatic response: <ul style="list-style-type: none"><li>• Complete response: As above for stage 3 intermediate risk</li><li>• Incomplete response: As above for stage 3 High risk</li></ul>

## B. Treatment schema for patients presenting without any prior treatment.

Pre-operative chemotherapy	
Localised disease:	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 4 Actinomycin-D (45mcg/kg) 2 weekly (week 1 and 3)
Metastatic disease:	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 6; Actinomycin-D (45mcg/kg) week 1,3 &5; Doxorubicin (50mg/m <sup>2</sup> ) week 1&5.
Stage 1 Low Risk(LR):	No further treatment.
Stage 1 Intermediate Risk(IR):	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 4; Actinomycin-D (45mcg/kg) week 2.
Stage 1 High Risk:	Vincristine (1.5 mg/m <sup>2</sup> ) weekly for 8 weeks, then weeks 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27 (20 doses in total); Actinomycin-D (45mcg/kg) at week 2, 5, 8, 11, 14, 17, 20, 23, 26 (9 doses); Doxorubicin (50mg/m <sup>2</sup> ) weeks 2, 8, 14, 20 and 26.
Stage 2 LR and IR stage 3 LR:	Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 8; then weeks 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27 (20 doses in total); Actinomycin-D (45mcg/kg) week 2, 5, 8, 11, 14, 17, 20, 23, 26 (9 doses).
Stage 3 Intermediate risk	Vincristine (1.5 mg/m <sup>2</sup> ) weekly for 8 weeks, then weeks 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27 (20 doses in total).  Actinomycin-D (45mcg/kg) at week 2, 5, 8, 11, 14, 17, 20, 23, 26 (9 doses); Doxorubicin (50mg/m <sup>2</sup> ) weeks 2, 8, 14, 20 and 26.
Stage 2/3 High Risk:	Cyclophosphamide (500 mg/m <sup>2</sup> )/ Doxorubicin (50mg/m <sup>2</sup> ) 6 weekly x 6 on weeks 1, 7, 13, 19, 25 and 31. Carboplatin (600mg/m <sup>2</sup> )/ Etoposide (300mg/m <sup>2</sup> ) 6 weekly x 6 on weeks 4, 10, 16, 22, 28 and 34
Stage 4 (All):	Pre-operative chemotherapy: Vincristine (1.5 mg/m <sup>2</sup> ) weekly x 6; Actinomycin-D (45mcg/kg) week 1,3 & 5; Doxorubicin (50mg/m <sup>2</sup> ) week 1 & 5. Evaluation of metastatic response: <ul style="list-style-type: none"> <li>○ If complete response: As above for stage 3 intermediate risk</li> <li>○ If incomplete response: As above for stage 3 High risk</li> </ul>
Radiotherapy details: Stage III intermediate risk patients received 14.4 Gy to the tumour bed and those with tumour positive lymph nodes received a boost of 10.8 Gy (total dose of up to 25.2 Gy) to the para-aortic lymph nodes as well.	
Patients with Stage II and stage III high risk disease received 25.2 Gy.	
Patients with macroscopic residual disease after surgery received radiotherapy boost dose of 10.8 Gy.	

